Company news

Takeda Pharmaceutical Co. Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

October 29, 2026

Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2026 (IFRS, Consolidated)

October 29, 2026

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

October 14, 2026

Takeda Pharmaceutical to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29

October 14, 2026

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

September 22, 2026

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

September 18, 2026

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

September 14, 2026

Takeda Pharmaceutical Announces Planned Retirement of President of Research & Development Andy Plump

September 10, 2026

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

September 9, 2026

Takeda Receives U.S. FDA Approval of MIMRYLO, Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 31, 2026

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 28, 2026

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 28, 2026

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 24, 2026

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 5, 2026

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

July 30, 2026

ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1

July 22, 2026

Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations

July 21, 2026

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

July 16, 2026

Takeda Pharmaceutical to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30

July 15, 2026

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

July 12, 2026

Filing of Corporate Governance Report to the Tokyo Stock Exchange

July 9, 2026

Takeda Pharmaceutical: Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees

July 8, 2026

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

June 24, 2026

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

June 15, 2026

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

June 11, 2026

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

June 9, 2026

Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan

June 9, 2026

Takeda Pharmaceutical Updates FY2025 Financial Results Based on Impact of AMITIZA® Antitrust Verdict

June 5, 2026

Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan

June 1, 2026

Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results

May 19, 2026

Takeda Pharmaceutical Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results

May 18, 2026

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

May 13, 2026

Model N Appoints Thomas Gibbs to Board of Directors

May 5, 2026

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

May 5, 2026

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

May 4, 2026

Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update

April 13, 2026

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

March 31, 2026

Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook

March 25, 2026

Rixubis (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Hemofil M (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

March 10, 2026

ADZYNMA (Takeda Pharmaceutical: ADAMTS13, recombinant-krhn) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

March 10, 2026

Alan Walshe Appointed General Manager of Takeda Canada

March 2, 2026

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 2, 2026

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

February 19, 2026

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

February 10, 2026

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

February 9, 2026

FRUZAQLA(TM) (fruquintinib capsules) now reimbursed in Ontario to treat metastatic colorectal cancer (mCRC)

February 2, 2026

Takeda Reports Third-Quarter FY2025 Results, Updates Full Year Outlook to Reflect VYVANSE Generics Impact, OPEX Discipline and FX Tailwind, Progressing Toward Three Transformative Launches Ahead

January 30, 2026

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

January 29, 2026

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

January 22, 2026

Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 88 decks. Every deck is listed under its year.